DHEA-S Lab Interpretation
DHEA-S is primarily useful for detecting very high levels (>700 μg/dL) that suggest an androgen-secreting tumor, but routine measurement has limited clinical utility in most populations and should not be used as a screening test for adrenal insufficiency or nonclassic congenital adrenal hyperplasia. 1
Clinical Significance by Context
In Hyperandrogenism/Hirsutism Evaluation
DHEA-S is elevated in only 16% of women with normal testosterone levels, and mildly elevated DHEA-S with normal free testosterone is unlikely to change management 1
The key androgen to measure is testosterone (preferably free or bioavailable testosterone), not DHEA-S 1
Critical threshold: DHEA-S >700 μg/dL raises concern for androgen-secreting tumor and warrants imaging 1
The height of DHEA-S elevation below this threshold has poor predictive value for specific diagnoses 1
In Adrenal Insufficiency Assessment
DHEA-S should NOT be used as a primary screening test for adrenal insufficiency, despite being uniformly low in treated patients with ACTH deficiency 2, 3
While low age- and gender-matched DHEA-S makes ACTH deficiency "extremely unlikely," when DHEA-S is low, further dynamic testing is still necessary 2
In younger patients (≤30 years) with pituitary macroadenomas, a z-score below -2.0 has 100% specificity for HPA insufficiency, but diagnostic value decreases significantly in older individuals 3
Recent meta-analysis shows: DHEA-S has 70-87% sensitivity and 87% specificity for diagnosing adrenal insufficiency, but this is based on limited heterogeneous evidence 4
In Adrenal Tumor Evaluation
DHEA-S is NOT a reliable predictor of hormonal activity in incidentally discovered adrenal tumors 5
In a cohort of 84 patients with adrenal incidentalomas, low DHEA-S had only 60% sensitivity and 75% specificity for detecting hormonal activity in benign cortical adenomas 5
DHEA-S measurement may only be valuable after confirming the cortical origin and benign nature of the tumor 5
In PCOS Diagnosis
DHEA-S is one of several androgens that can be measured, but testosterone (particularly free testosterone) remains the primary androgen for diagnosis 6
- The 2023 International PCOS Guidelines acknowledge ongoing challenges in determining which specific androgen measurements are most accurate 6
Important Caveats
Age and Gender Dependency
- DHEA-S levels vary dramatically by age and gender, requiring age- and gender-specific reference ranges 7, 3
- Levels peak around age 25-30 and decline progressively with age 7
- After age 45, DHEA-S is higher in men than women 7
Assay Limitations
- Most hospital immunoassays lack adequate sensitivity and specificity for measuring androgens in women 1
- LC-MS/MS is the reference standard but has limited accessibility 6, 8
- There is no uniform laboratory standard, leading to wide inter-assay variability 1
When NOT to Order DHEA-S
- Do not use for screening nonclassic congenital adrenal hyperplasia - measure early-morning follicular-phase 17-hydroxyprogesterone instead in high-risk populations 1
- Do not rely on it as the sole test for adrenal insufficiency - dynamic testing remains necessary 2, 3
- Do not use routinely in hirsutism workup when free testosterone is normal 1
Practical Algorithm
Order DHEA-S when:
- Evaluating suspected androgen-secreting tumor (looking for levels >700 μg/dL)
- As part of comprehensive hyperandrogenism workup in PCOS (but not as primary test)
- In younger patients (<30 years) with pituitary macroadenomas as adjunct to HPA axis assessment
Do NOT order DHEA-S as:
- Primary screening for adrenal insufficiency
- Screening for nonclassic CAH
- Sole test for evaluating adrenal incidentalomas
- Routine test when free testosterone is already normal in hirsutism evaluation